Home › Free Stock Grades › VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Stock Grade
VRTX · Healthcare
A+
Market Cap
$128.4B
P/E Ratio
29.3
Revenue Growth (YoY)
+9.6%
Net Margin
32.7%
Return on Equity
21.2%
Dividend Yield
None
About Vertex Pharmaceuticals Incorporated's fundamentals
Vertex Pharmaceuticals is a large-cap biotech company with a market capitalization of $115.9 billion that generates substantial profitability, evidenced by a net margin of 32.7% and return on equity of 21.2%. The company demonstrated moderate revenue growth of 9.6% year-over-year, while trading at a P/E ratio of 29.3. Vertex does not currently pay a dividend, instead likely reinvesting earnings into research and development operations typical of the biotechnology sector.